Why Zepbound (Tirzepatide) Causes Constipation: The Biology Explained

How GLP-1 Receptor Activation Slows Your Gut

Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the constipation it causes traces back primarily to its GLP-1 component. Native GLP-1, secreted by intestinal L-cells after a meal, acts as a brake on gastrointestinal transit. This is called the "ileal brake" reflex. Tirzepatide activates the same pathway at supraphysiological levels, amplifying that brake well beyond what normal post-meal signaling produces.

GLP-1 receptors are distributed across the enteric nervous system, vagal afferent neurons, and gastrointestinal smooth muscle 1. When tirzepatide binds these receptors, it triggers a cascade that inhibits acetylcholine release from excitatory motor neurons in the myenteric plexus. Acetylcholine is the primary neurotransmitter driving propulsive contractions (peristalsis) in the colon. Less acetylcholine means fewer and weaker contractions pushing stool forward.

A 2012 study using scintigraphy showed that exenatide (a GLP-1 agonist) delayed gastric emptying by approximately 25 minutes on average and significantly slowed colonic transit 2. Tirzepatide produces comparable gastric emptying delays. In a pharmacodynamic sub-study of the SURMOUNT program, tirzepatide 15 mg delayed gastric half-emptying time by roughly 30 to 50 minutes compared to placebo at steady state 3.

The vagus nerve is the other major player. GLP-1 receptors on vagal afferents in the gut wall send inhibitory signals to the brainstem's dorsal vagal complex, which then reduces efferent parasympathetic outflow to the stomach and intestine 4. This centrally mediated suppression of motility stacks on top of the local enteric effects.

The GIP Receptor Component and Why It Matters

Tirzepatide is not a pure GLP-1 agonist. It also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor, and this dual mechanism may partially modulate the severity of constipation compared to GLP-1-only drugs like semaglutide.

GIP receptors are expressed on enteric neurons and in gastric tissue, but their effect on motility appears directionally different from GLP-1. Preclinical data suggests GIP signaling may promote, rather than inhibit, gastric motility under certain conditions 5. A 2023 analysis comparing GI adverse event profiles across incretin-based therapies found that tirzepatide produced numerically lower rates of constipation than semaglutide 2.4 mg at comparable weight-loss efficacy 6. In SURMOUNT-1 (N=2,539), constipation rates were 6.0% at 5 mg, 5.9% at 10 mg, and 11.0% at 15 mg vs. 3.9% on placebo 7. By comparison, the STEP-1 trial (N=1,961) reported constipation at 24.0% for semaglutide 2.4 mg vs. 11.2% for placebo 8.

This difference is not definitive proof of GIP-mediated protection. Cross-trial comparisons carry significant limitations. But the pattern is consistent enough that researchers have hypothesized the GIP agonism partially counterbalances GLP-1-driven dysmotility.

What Happens at the Cellular Level in the Colon

The downstream biology of constipation on tirzepatide involves three linked processes: reduced propulsion, increased water absorption, and altered electrolyte secretion.

When peristaltic contractions slow, stool remains in the colon longer. The human colon absorbs approximately 1.5 liters of water per day from luminal contents 9. Extended transit time means the colonic epithelium extracts more water than normal, producing harder, drier stool. This is the same mechanism that explains opioid-induced constipation, though the upstream trigger is different.

GLP-1 receptor activation also influences chloride and bicarbonate secretion in the colonic epithelium. Reduced chloride secretion via the cystic fibrosis transmembrane conductance regulator (CFTR) channel decreases the osmotic gradient that draws water into the lumen 10. With less fluid entering the colon and more being absorbed, stool dehydrates.

A third factor is caloric. Patients on tirzepatide eat significantly less. In SURMOUNT-1, participants on tirzepatide 15 mg reduced caloric intake by an estimated 24% to 30% 7. Less food in means less residue reaching the colon, which reduces stool bulk. Smaller stool volumes are less effective at triggering the stretch-sensitive mechanoreceptors that initiate the defecation reflex.

Dr. Michael Camilleri, a gastroenterologist at Mayo Clinic who has published extensively on GLP-1 effects on gut motility, stated: "The combination of delayed transit and reduced meal volume creates a double hit on stool frequency that most patients experience as constipation, particularly during the early weeks of therapy" 11.

Dose-Dependent Pattern: What the Trial Data Shows

Constipation on tirzepatide follows a clear dose-response pattern, and the timing clusters around dose escalation periods.

In the pooled SURMOUNT analysis, constipation was more common at higher maintenance doses. The 5 mg arm showed rates similar to placebo (6.0% vs. 3.9%), while the 15 mg arm reached 11.0% 7. SURMOUNT-2, which enrolled adults with type 2 diabetes and obesity (N=938), confirmed this: constipation occurred in 6.2% on 10 mg and 8.1% on 15 mg vs. 2.2% on placebo 12.

Most constipation events were graded as mild to moderate using CTCAE criteria. Severe constipation (grade 3+) occurred in fewer than 1% of participants across all SURMOUNT trials, and discontinuation due to constipation specifically was rare 7.

The temporal pattern matters clinically. Reports from the FDA Adverse Event Reporting System (FAERS) and clinical practice consistently show that constipation onset concentrates in the first 2 to 6 weeks at each new dose level 13. This aligns with pharmacokinetics: tirzepatide reaches steady state at approximately 4 to 5 weeks after each dose change. Once steady state is achieved and the gut adapts, many patients report improvement.

The 2023 American Gastroenterological Association (AGA) clinical practice update on GLP-1 receptor agonist-related GI adverse effects noted: "Gastrointestinal symptoms including constipation are most pronounced during dose titration and tend to attenuate with continued use at a stable dose" 14.

Why Some Patients Get Constipation and Others Do Not

Not every patient on tirzepatide develops constipation. Individual variation in GLP-1 receptor density, baseline gut transit time, diet composition, and hydration status all influence susceptibility.

Patients with pre-existing slow-transit constipation or irritable bowel syndrome with constipation (IBS-C) are at higher risk. Their baseline colonic motility is already compromised, so the additional suppression from GLP-1 receptor activation pushes them past a clinical threshold more easily. Older adults also show higher susceptibility, likely because aging reduces enteric neuronal density and basal gut motility 15.

Concurrent medications compound the risk. Opioids, anticholinergics, calcium channel blockers, and iron supplements all slow gut transit independently. Stacking tirzepatide on top of one or more of these creates an additive or synergistic motility suppression. A retrospective claims analysis published in 2024 found that patients on concurrent opioid therapy were 2.3 times more likely to report constipation on GLP-1 agonists than those without opioid co-prescriptions 16.

Genetics also play a role. Polymorphisms in the GLP-1 receptor gene (GLP1R) have been associated with variable receptor sensitivity. A 2020 genome-wide association study identified variants in GLP1R linked to differential GI side effect profiles, though this research remains preliminary and is not yet used for clinical decision-making 17.

How to Manage Constipation on Zepbound

Management follows the same principles used for any drug-induced constipation, with a few tirzepatide-specific considerations.

First-line measures are behavioral. Increase daily fluid intake to at least 2 liters (water, not caffeinated or carbonated beverages exclusively). Add 25 to 30 grams of fiber daily, with a preference for soluble fiber sources like psyllium husk. Psyllium draws water into the stool and adds bulk, partially compensating for the reduced luminal fluid caused by GLP-1 receptor activation. A meta-analysis of 16 RCTs found psyllium significantly increased stool frequency and improved stool consistency, with a number needed to treat (NNT) of 3 for functional constipation 18.

Physical activity helps. Even moderate walking (30 minutes daily) stimulates colonic motor activity through mechanical vibration and parasympathetic activation.

When behavioral changes are insufficient, osmotic laxatives are the standard pharmacologic step. Polyethylene glycol 3350 (MiraLAX) at 17 grams daily is well-studied, well-tolerated, and does not interact with tirzepatide absorption. Magnesium citrate is an alternative, though it should be used cautiously in patients with renal impairment.

Stimulant laxatives (bisacodyl, senna) work for intermittent use but are not recommended as daily long-term therapy. If osmotic laxatives fail, prescription agents such as lubiprostone (Amitiza, 24 mcg twice daily) or linaclotide (Linzess, 145 mcg daily) directly stimulate chloride secretion, counteracting the secretory suppression caused by GLP-1 receptor activation 19.

Dose adjustment of tirzepatide itself is a consideration. If constipation is severe and refractory, extending the titration schedule (staying at a lower dose longer before escalating) gives the enteric nervous system more time to adapt. Eli Lilly's prescribing information states that dose escalation may be delayed based on tolerability 20.

When Constipation Signals Something More Serious

Most constipation on tirzepatide is benign and self-limiting. But certain red flags require immediate clinical evaluation.

New-onset constipation accompanied by abdominal distension, vomiting, or inability to pass gas may signal ileus or bowel obstruction. GLP-1 agonists have been associated with rare cases of intestinal obstruction in FAERS reports 13. Patients with a history of abdominal surgery, adhesions, or prior obstruction are at elevated risk.

If constipation persists beyond 8 weeks at a stable dose despite adequate fiber, hydration, and osmotic laxatives, further workup is warranted. This may include abdominal X-ray to assess stool burden, anorectal manometry to evaluate pelvic floor dysfunction, or a colonic transit study using radiopaque markers.

Blood in the stool, unintentional weight loss beyond what is expected from tirzepatide therapy, or a family history of colorectal cancer should trigger colonoscopy referral regardless of the presumed drug-related cause.

Contact your prescriber if you have not had a bowel movement in 4 or more consecutive days, if you develop rectal bleeding, or if abdominal pain becomes severe enough to interfere with daily activities.